Pancreatic Ductal Carcinoma Clinical Trial
Official title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with placebo combined with nab-paclitaxel plus gemcitabine (AG treatment), in participants with hyaluronan (HA)-high Stage IV previously untreated pancreatic ductal adenocarcinoma (PDA).
Participants will be randomized in a 2:1 ratio to PAG or AG treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04045496 -
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT02243007 -
Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT06182072 -
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1 | |
| Completed |
NCT04596865 -
Recurrence After Whipple's (RAW) Study
|
||
| Recruiting |
NCT04121286 -
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
|
Phase 1 | |
| Recruiting |
NCT05293496 -
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05288205 -
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
|
Phase 1/Phase 2 |